Pneumococcal Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Pneumococcal Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

The global pneumococcal vaccine market size reached US$ 8.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 11.6 Billion by 2027, exhibiting a growth rate (CAGR) of 5.4% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Pneumococcal disease is caused by Streptococcus pneumoniae bacterium that can lead to severe infection of the lungs (pneumonia) and blood (bacteremia) or the lining of the brain and spinal cord (meningitis). The vaccines help protect both children and adults by stimulating the immune system and protecting against the bacterial strains responsible for severe infections. As these vaccines help prevent infection from spreading, reduce fatality rate and eliminate the need for hospitalization, they are widely being used across the globe.

According to the World Health Organization (WHO), children under 2-5 years of age are at a high risk of developing pneumococcal disease. This, in confluence with the escalating number of birth rates and the growing concerns among parents about the health of their children, represents one of the major factors bolstering the market growth. Additionally, the increasing geriatric population is contributing to the market growth. This can also be accredited to the contagiousness of the disease, which can cause severe complications in older adults. Furthermore, the rising number of smokers and individuals living with chronic health conditions is positively influencing the market growth. Moreover, the introduction of the Pneumococcal Conjugate Vaccine (PCV) in infant routine immunization by governing agencies of numerous countries is anticipated to propel the market growth.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global pneumococcal vaccine market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on vaccine type, product type, distribution channel and end user.

Breakup by Vaccine Type:

Pneumococcal Conjugate Vaccine
Pneumococcal Polysaccharide Vaccine

Breakup by Product Type:

Prevnar 13
Synflorix
Pneumovax 23

Breakup by Distribution Channel:

Distribution Partner Companies
Non-Governmental Organizations (NGO)
Government Authorities

Breakup by End User:

Pediatrics
Adults

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., GlaxoSmithKline Plc., Merck & Co. Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt Ltd and Walvax Biotechnology Co. Ltd.

Key Questions Answered in This Report:
How has the global pneumococcal vaccine market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global pneumococcal vaccine market?
What are the key regional markets?
What is the breakup of the market based on the vaccine type?
What is the breakup of the market based on the product type?
What is the breakup of the market based on the distribution channel?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global pneumococcal vaccine market and who are the key players?
What is the degree of competition in the industry?